Jubilant and Mnemosyne Pharmaceuticals Announce Drug
Discovery Collaboration
Jubilant Biosys Limited, Bangalore announced today that they have
entered into drug discovery collaboration with Mnemosyne
Pharmaceutical Inc, Providence, Rhode Island that will seek to
identify preclinical candidates in the area of neuropsychiatric
diseases. The collaboration will focus on developing subunit
selective NMDA receptor modulators (SNRMs) that Mnemosyne has
identified. The alliance shall initially span a period of 2 years
and may be extended on mutual consent across other therapeutic
programs as well.
The multi-target program agreement will be enabled by the expertise
of Mnemosyne in NMDA receptor pharmacology and supported by
Jubilant's translational center in Malvern, Pennsylvania and by
scientists from Jubilant's India based facilities. The
collaboration will leverage the capabilities of the companies
across medicinal chemistry, NMDA receptor pharmacology,
electrophysiology, computational chemistry and DMPK and in vivo
pharmacology as appropriate in progressing promising compounds that
have been identified by Mnemosyne. Under the terms of the alliance
agreement, Mnemosyne will exclusively own all IP generated and
shall be responsible for clinical development and
commercialization.
Commenting on this achievement, Sri Mosur, CEO & President,
Global Drug Discovery & Development, Jubilant said: "We are
pleased to collaborate with Mnemosyne Pharmaceuticals Inc, on the
SNRM platform,We are excited about the Mnemosyne programs and
enthused that our ion channel expertise in Malvern, Pennsylvania
supported by already demonstrated capabilities in India will be
leveraged in this collaboration to deliver optimal outcomes in the
difficult area of neuroscience research. This creative alliance
further demonstrates Jubilant's commitment to global R&D in
enabling early discovery research towards optimal
commercialization."
Commenting on the collaboration Mnemosyne CEO, Dr. Kollol Pal said
that "Mnemosyne is very impressed with the integrated chemistry and
biology expertise that has been assembled by Jubilant, particularly
in the area of ion channels and neuroscience. We are looking
forward to a successful collaboration with Jubilant that will
produce first-in-class drugs that address the unmet medical need in
neuropsychiatric diseases such as schizophrenia and Alzheimer's
disease."
About Us
Jubilant Biosys Ltd. is a Bengaluru based subsidiary of Jubilant
Life Sciences Ltd, headquartered in Noida, India. Jubilant Biosys,
provides integrated drug discovery and development solutions to the
global pharmaceutical industry. It is a pioneer in collaborative
discovery research and development and is engaged in multiple
partnerships with global pharmaceutical industry in therapeutic
areas of Oncology, CNS and CVMED.
http://www.jubilantbiosys.com
About Mnemosyne
Mnemosyne Pharmaceuticals, Inc. is a privately-held, biotechnology
company focused on the discovery and development of small molecule
therapeutics for the neuropsychiatry market. The company's drug
discovery efforts are focused on targeting the NMDA receptor, which
is known to be the "master" switch for learning and memory.
Mnemosyne's lead program is for schizophrenia, and the company is
exploring additional indications including Alzheimer's disease,
recovery from stroke and traumatic brain injury and attention
deficit/hyperactivity disorder.
http://www.mnemosynepharma.com
SOURCE﹛Jubilant Biosys Ltd